WeTrade (WETG) Stock Soars 39% on Monkeypox Test Sales News

Source: Viacheslav Lopatin / Shutterstock.com

WeTrade (NASDAQ:WETG) stock is rocketing higher on Friday after revealing a sale agreement for monkeypox test kits with Parkway Medical.

This deal has Parkway Medical agreeing to acquire $50 million worth of monkeypox virus test kits as well as antigen test kits. That covers 5 million nucleic acid tests and 6 million antigen tests. Parkway Medical has already paid a $1 million deposit as part of the deal.

Pijun Liu, CEO of WeTrade, had the following to say about the monkeypox test kit news boosting WETG stock today.

“We are excited about the sales of monkeypox virus kits and antigen tests to Parkway Medical after obtaining the exclusive sales channel from Jiqing Biomedical Technology Co. Ltd. […] We are delighted to work with Parkway Medical to provide the test kits and antigen tests to overseas market as we aim to contribute to the prevention and control of the outbreak.”

To go along with this news, WETG stock is seeing an increase in trading volume on Friday. As of this writing, more than 395,000 shares of the stock are on the move. To put that in perspective, the company’s daily average trading volume is only about 82,000 shares.

WETG stock is up 39% as of Friday morning and up 500% since the start of the year.

There’s more recent stock market news for traders to dive into below!

That’s thanks to InvestorPlace offering all the latest coverage for Friday! Among that is what has shares of SmileDirectClub (NASDAQ:SDC), CF Acquisition Corp VI (NASDAQ:CFVI) and Chinese stocks moving today. You can find out more on these matters at the following links!

More Friday Stock Market News

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.

Read More:Penny Stocks — How to Profit Without Getting Scammed

On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Leave a Reply

Your email address will not be published. Required fields are marked *